Patient adherence and efficacy of certolizumab pegol in the management of Crohn's disease.
Treatment with Anti-Tumor Necrosis Factor (anti-TNF) therapy has become a mainstay of therapy for patients with CD who are unresponsive to conventional medical management. Currently there are three anti-TNFα antibodies that have been approved by the US Food and Drug Administration for the treatment of CD, namely infliximab, adalimumab and certolizumab pegol (CZP). Several double blind placebo controlled trials determined that CZP is effective as induction and maintenance treatment in adult patients with CD regardless of their prior exposure to other anti-TNFα antibodies. This review discusses the efficacy of CZP and adherence to therapy with anti-TNFα antibodies in patients with CD.
Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA. ; Department of Gastroenterology, Medical University, Wroclaw, Poland.
Wojciech
W
Blonski
Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA.
Anna M
AM
Buchner
Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA.
Gary R
GR
Lichtenstein
Crohn’s disease; adherence; anti-TNFα agents; certolizumab pegol